Home Cart 0 Sign in  
X

[ CAS No. 83-53-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 83-53-4
Chemical Structure| 83-53-4
Chemical Structure| 83-53-4
Structure of 83-53-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 83-53-4 ]

Related Doc. of [ 83-53-4 ]

Alternatived Products of [ 83-53-4 ]

Product Details of [ 83-53-4 ]

CAS No. :83-53-4 MDL No. :MFCD00041823
Formula : C10H6Br2 Boiling Point : -
Linear Structure Formula :- InChI Key :IBGUDZMIAZLJNY-UHFFFAOYSA-N
M.W : 285.96 Pubchem ID :66521
Synonyms :

Calculated chemistry of [ 83-53-4 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 0.0
Num. H-bond donors : 0.0
Molar Refractivity : 59.35
TPSA : 0.0 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.21 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.7
Log Po/w (XLOGP3) : 3.99
Log Po/w (WLOGP) : 4.36
Log Po/w (MLOGP) : 4.72
Log Po/w (SILICOS-IT) : 4.32
Consensus Log Po/w : 4.02

Druglikeness

Lipinski : 1.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.74
Solubility : 0.00516 mg/ml ; 0.0000181 mol/l
Class : Moderately soluble
Log S (Ali) : -3.69
Solubility : 0.0582 mg/ml ; 0.000203 mol/l
Class : Soluble
Log S (SILICOS-IT) : -5.77
Solubility : 0.000483 mg/ml ; 0.00000169 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.7

Safety of [ 83-53-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 83-53-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 83-53-4 ]
  • Downstream synthetic route of [ 83-53-4 ]

[ 83-53-4 ] Synthesis Path-Upstream   1~15

  • 1
  • [ 83-53-4 ]
  • [ 97674-02-7 ]
  • [ 46258-62-2 ]
Reference: [1] Patent: WO2012/21591, 2012, A1, . Location in patent: Page/Page column 114-115
  • 2
  • [ 83-53-4 ]
  • [ 74-88-4 ]
  • [ 6627-78-7 ]
YieldReaction ConditionsOperation in experiment
73%
Stage #1: With n-butyllithium In diethyl ether; benzene at 0℃; for 1 h; Inert atmosphere
Stage #2: at 20℃;
The compounded 4' (10 mmol, 2.21 g) was added to a mixture of 30 ml of ether and 30 ml of benzene, and n-butyllithium (10 mmol, 1.6 M, 6.25 ml) was slowly added dropwise at 0°C under nitrogen atmosphere. After stirring at 0° C. for 1 hour, methyl iodide (15 mmol, 2.13 g) was slowly added dropwise to the reaction system. After completion of the dropwise addition, the reaction was warmed up to room temperature. The reaction was completed by TLC and the reaction was completed. 60 ml of a saturated aqueous solution of ammonium chloride was added to the reaction system, the aqueous layer was extracted with toluene, the organic layers were combined, washed with saturated brine (100ml*3), dried over anhydrous sodium sulfate, and the organic phase was concentrated and purified by column chromatography. Compound 4''' (7.3 mmol, 1.61 g, 73percent).
Reference: [1] Patent: CN107814795, 2018, A, . Location in patent: Paragraph 0028; 0029
  • 3
  • [ 83-53-4 ]
  • [ 13720-06-4 ]
Reference: [1] Chemische Berichte, 1931, vol. 64, p. 953
  • 4
  • [ 7647-01-0 ]
  • [ 75-15-0 ]
  • [ 7446-70-0 ]
  • [ 83-53-4 ]
  • [ 13720-06-4 ]
Reference: [1] Chemische Berichte, 1931, vol. 64, p. 953
  • 5
  • [ 83-53-4 ]
  • [ 124-38-9 ]
  • [ 16650-55-8 ]
Reference: [1] Organic Process Research and Development, 2011, vol. 15, # 1, p. 112 - 122
[2] Bioorganic and Medicinal Chemistry Letters, 2001, vol. 11, # 20, p. 2769 - 2773
[3] Journal of the Chemical Society, 1958, p. 1426
  • 6
  • [ 83-53-4 ]
  • [ 63279-58-3 ]
Reference: [1] Patent: US2012/273724, 2012, A1, . Location in patent: Page/Page column 15
  • 7
  • [ 83-53-4 ]
  • [ 63279-58-3 ]
Reference: [1] Patent: US2012/267571, 2012, A1,
  • 8
  • [ 67-56-1 ]
  • [ 83-53-4 ]
  • [ 5467-58-3 ]
Reference: [1] Collection of Czechoslovak Chemical Communications, 2000, vol. 65, # 11, p. 1791 - 1804
  • 9
  • [ 83-53-4 ]
  • [ 79996-99-9 ]
Reference: [1] Tetrahedron, 2001, vol. 57, # 25, p. 5339 - 5352
  • 10
  • [ 83-53-4 ]
  • [ 68-12-2 ]
  • [ 50672-84-9 ]
YieldReaction ConditionsOperation in experiment
62%
Stage #1: With n-butyllithium In diethyl ether; hexane at 0℃; for 0.333333 h;
Stage #2: at 0 - 20℃; for 1 h;
To a 150 ml flask was added 1,4-dibromonaphthalene (2.0 g, 7.0 mmol) and anhydrous ether (50 ml). After cooling to 0 °C n-BuLi (3.1 ml of 2.5 M in hexanes, 7.7 mmol) was added dropwise and stirred for 20 minutes after which anhydrous DMF (1.62 ml, 21 mmol) was added. The reaction was then warmed to ambient temperature and after 1 h the reaction was quenched with water (10 ml), stirred for 10 minutes, and extracted with ether (3x). The ether layer was dried over anhydrous NA2S04, passed through a silica plug, and concentrated to afford 1.02 g (62percent) of product as a pure off- white solid : LH NMR (300 MHz, DMSO-D6) : 8 7.80-7. 85 (2H, m), 8.10 (1H, d, J = 7.7 Hz), 8.20 (1H, d, J = 7.7 Hz), 8. 32 (1H, m). 9.24 (1H, m), 10.42 (1H, s). Anal. for CIIH7BRO : Calc'd: C: 56.20 H: 3.00 Found: C: 56.13 H: 2.98
62%
Stage #1: With n-butyllithium In diethyl ether; hexane at 0℃; for 0.333333 h;
Stage #2: at 20℃; for 1 h;
Step 1: 4-Bromo-1 -naphthaldehyde (P20a)To a solution of 1,4-dibromonaphthalene (2.0 g, 7.0 mmol) in dry Et20 (50 mL) was added n5 BuLi (2.5M in hexanes, 3.1 mL, 7.7 mmol) at 0°C and the solution was stirred for 20 mm. ThenDMF (1.62 mL, 21 mmol) was added and the solution was warmed to rt and stirred at this temperature for 1 h, quenched with water and extracted with Et20 (3x). The combined organic layers were washed with brine, dried over Na2504, filtered, concentrated and purified by CC (PE/EA = 50/1) to give compound P20a (1.02 g, 62percent) as an off- white solid.
Reference: [1] RSC Advances, 2014, vol. 4, # 63, p. 33474 - 33477
[2] Patent: WO2004/103941, 2004, A2, . Location in patent: Page 16
[3] Patent: WO2013/178362, 2013, A1, . Location in patent: Page/Page column 107
[4] Angewandte Chemie - International Edition, 2017, vol. 56, # 42, p. 13094 - 13098[5] Angew. Chem., 2017, vol. 56, p. 13274 - 13278,5
[6] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 4, p. 902 - 906
[7] Patent: EP2159217, 2010, A1, . Location in patent: Page/Page column 58
  • 11
  • [ 83-53-4 ]
  • [ 50672-84-9 ]
YieldReaction ConditionsOperation in experiment
56% With n-butyllithium In tetrahydrofuran; <i>N</i>-methyl-acetamide; water Example 39
Preparation of 5,6-dichloro-2-[4-[(2,4-dioxothiazolidin-5-ylidene)methyl]naphth-1-yl]benzimidazole
To a solution of 1,4-dibromonaphthalene (1.00 g, 3.50 mmol) in tetrahydrofuran (15 mL) were added n-butyllithium (1.6 mol/L; 3.1 mL) and dimethylformamide (0.54 mL, 7.0 mmol) sequentially at =78° C. under nitrogen atmosphere, and the mixture was stirred for 15 min.
Water was added, and the mixture was extracted with ethyl acetate.
The organic layer was combined, washed with brine and dried on anhydrous sodium sulfate.
The solvent was removed under reduced pressure, and the residue was purified by column chromatography (8:1 hexane/ethyl acetate) to afford 4-bromo-1-naphthalenecarboxaldehyde (458 mg, 56percent).
1H NMR (400 MHz, CDCl3) δ (ppm) 7.6-7.8 (m, 2H), 7.78 (d, J=7.8 Hz, 1H), 7.94 (d, J=7.8 Hz, 1H), 8.34 (dd, J=8.2, 1.6 Hz, 1H), 9.25 (dd, J=8.2,1.6 Hz, 1H), 10.3 (s, 1H)
Reference: [1] Patent: US2002/120144, 2002, A1,
  • 12
  • [ 83-53-4 ]
  • [ 92616-49-4 ]
YieldReaction ConditionsOperation in experiment
31% at 125℃; for 16 h; CuCN (5.0g, 56.3mmol) was added to a solution of 1,4-dibromonaphthalene (20g, 70.4mmol) in DMF (250mL),the mixture was reacted for 16hrs at 125°C, evaporated under reduced pressure. Aqueous ammonia (200mL) and EA(200mL) were added to the residue, the mixture was stirred for 1h and organic phase was seperated. The organic phasewas in turn washed with water (100mL33) and saturated brine (100mL), dried over anhydrous magnesium sulfate,filtered, evaporated under reduced pressure. The residue was purified with silica chromatography (PE:EA = 10:1) togive compound 3-d (5.1g, yield 31percent). LC-MS (ESI): m/z = 232 [M+H]+.
26% at 125℃; [00285] Step A: 4-Bromo- 1 -naphthonitrileA mixture of 1 ,4-dibromonaphthalene (24.06g, 84mmol) and copper cyanide (6.02g, 67mmol) in DMF (85mL) was heated to 125°C overnight. The mixture was partially concentrated to remove DMF and the resulting residue washed with aqueous ammonium hydroxide and extracted with ethyl acetate. The organic layer was concentrated and purified by chromatography to yield 4-bromo-l -naphthonitrile (5.13g, 26percent).
26% at 130℃; for 12 h; Inert atmosphere General procedure: A mixture of 3a-3g (0.1 mol for 3a-3e and 3g; 0.4 molfor 3f) and CuCN (26.87 g, 0.3 mol for 3a-3e and 3g; 21.49g, 0.24 mol for 3f) in DMF (300 mL) were stirred at 130°C in N2 atmosphere for 12 h, when TLC analysis indicated completion of reaction. On cooling to room temperature, the reaction mixture was diluted with CH2Cl2 (900 mL) and the resulting mixture was further stirred for 1 h and filtered off. The filtrate was washed with 5percent brine (500 mL 5), dried (Na2SO4) and evaporated on a rotary evaporator to afford a black oil, which was purified by column chromatography to afford the pureproduct 4a-4g.
Reference: [1] Patent: EP3275867, 2018, A1, . Location in patent: Paragraph 0102; 0103
[2] Patent: WO2011/159839, 2011, A2, . Location in patent: Page/Page column 98
[3] Medicinal Chemistry, 2017, vol. 13, # 3, p. 260 - 281
  • 13
  • [ 83-53-4 ]
  • [ 544-92-3 ]
  • [ 92616-49-4 ]
Reference: [1] Collection of Czechoslovak Chemical Communications, 2000, vol. 65, # 11, p. 1791 - 1804
  • 14
  • [ 83-53-4 ]
  • [ 103986-53-4 ]
Reference: [1] Patent: CN107814795, 2018, A,
  • 15
  • [ 83-53-4 ]
  • [ 1533519-85-5 ]
Reference: [1] Patent: CN107955029, 2018, A,
Same Skeleton Products
Historical Records